DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Phase 2

Completed

Conditions: Hematopoietic Neoplasm

Interventions: Drug: SAR302503

First Posted Date: 2011-08-22

Last Posted Date: 2025-03-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 81

Registration Number: NCT01420783

Locations: 🇺🇸
Investigational Site Number 840008, Scottsdale, Arizona, United States
🇺🇸
Investigational Site Number 840004, La Jolla, California, United States
🇺🇸
Investigational Site Number 840005, Los Angeles, California, United States

and more 32 locations

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Phase 2

Completed

Conditions: Hematopoietic Neoplasm

Interventions: Drug: SAR302503

First Posted Date: 2011-08-22

Last Posted Date: 2025-03-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT01420770

Locations: 🇺🇸
Investigational Site Number 840001, San Francisco, California, United States
🇺🇸
Investigational Site Number 840003, Ann Arbor, Michigan, United States
🇺🇸
Investigational Site Number 840006, Rochester, Minnesota, United States

and more 1 locations

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: BMS-833923 (XL139)

First Posted Date: 2011-08-10

Last Posted Date: 2013-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT01413906

Locations: 🇯🇵
Local Institution, Kashiwa-shi, Chiba, Japan

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: BMS-817399

First Posted Date: 2011-07-28

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 123

Registration Number: NCT01404585

Locations: 🇺🇸
Pharma Resource, East Providence, Rhode Island, United States
🇺🇸
Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States
🇪🇸
Local Institution, Sevilla, Spain

and more 3 locations

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Atazanavir (POU2)
Drug: Atazanavir (current formulation)
Drug: Atazanavir, powder for oral use 1 (POU1)

First Posted Date: 2011-07-28

Last Posted Date: 2013-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT01404572

Locations: 🇺🇸
Pra International, Lenexa, Kansas, United States

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Ipilimumab (BMS-734016)
Drug: Vemurafenib

First Posted Date: 2011-07-22

Last Posted Date: 2015-01-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01400451

Locations: 🇺🇸
University Of California Los Angeles, Los Angeles, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana Farber Cancer Inst, Boston, Massachusetts, United States

and more 1 locations

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Phase 1

Completed

Conditions: Depression

Interventions: Drug: Placebo matching BMS-820836
Drug: BMS-820836

First Posted Date: 2011-07-18

Last Posted Date: 2013-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 57

Registration Number: NCT01396252

Locations: 🇯🇵
Local Institution, Taito-Ku, Tokyo, Japan

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab (BMS-901608; HuLuc63)

First Posted Date: 2011-07-14

Last Posted Date: 2017-08-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT01393964

Locations: 🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸
Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸
Tennessee Oncology, Pllc, Nashville, Tennessee, United States

and more 8 locations

Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)

Completed

Conditions: Chronic Myeloid Leukemia

First Posted Date: 2011-07-14

Last Posted Date: 2016-07-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT01394666

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Phase 1

Completed

Conditions: Pharmacokinetic Study in Healthy Participants

Interventions: Drug: Dasatinib as dispersed tablets
Drug: Dasatinib as tablets
Drug: Dasatinib as liquid

First Posted Date: 2011-07-12

Last Posted Date: 2013-02-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 141

Registration Number: NCT01392703

Locations: 🇺🇸
Healthcare Discoveries Inc., San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy